HRTX
HRTX
NASDAQ · Biotechnology

Heron Therapeutics Inc

$0.34
+0.00 (+1.44%)
As of Aug 15, 2:08 AM ET ·
Financial Highlights (FY 2026)
Revenue
173.91M
Net Income
-22,665,767
Gross Margin
73.3%
Profit Margin
-13.0%
Rev Growth
+12.9%
D/E Ratio
9.81
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 73.3% 73.3% 40.4% 40.4%
Operating Margin -9.0% -8.1% -7.6% -6.6%
Profit Margin -13.0% -12.4% -6.9% -7.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 173.91M 154.07M 36.22M 29.20M
Gross Profit 127.50M 112.95M 14.65M 11.81M
Operating Income -15,582,728 -12,424,216 -2,748,870 -1,921,517
Net Income -22,665,767 -18,071,571 -2,507,722 -2,038,148
Gross Margin 73.3% 73.3% 40.4% 40.4%
Operating Margin -9.0% -8.1% -7.6% -6.6%
Profit Margin -13.0% -12.4% -6.9% -7.0%
Rev Growth +12.9% +12.9% +20.2% -6.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 28.81M 28.81M 87.16M 81.85M
Total Equity 2.94M 2.94M 118.11M 119.94M
D/E Ratio 9.81 9.81 0.74 0.68
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -12,989,300 -10,931,816 -3,086,652 -2,725,751
Free Cash Flow -2,753,402 -2,024,759